Display options
Cite
Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1(1):e000036doi: 10.1136/rmdopen-2014-000036.
Woerner, A., Uettwiller, F., Melki, I., Mouy, R., Wouters, C., Bader-Meunier, B., & Quartier, P. (2015). Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD open, 1(1), e000036. https://doi.org/10.1136/rmdopen-2014-000036
Woerner, A, et al. "Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent." RMD open vol. 1,1 (2015): e000036. doi: https://doi.org/10.1136/rmdopen-2014-000036
Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, Quartier P. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015 Apr 30;1(1):e000036. doi: 10.1136/rmdopen-2014-000036. eCollection 2015. PMID: 26509061; PMCID: PMC4613174.
Copy Download .nbib Format: NLM
Share it on

RMD Open. 2015 Apr 30;1(1):e000036. doi: 10.1136/rmdopen-2014-000036. eCollection 2015.

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.

RMD open

A Woerner, F Uettwiller, I Melki, R Mouy, C Wouters, B Bader-Meunier, P Quartier

Affiliations

  1. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France ; Department of Pediatric Rheumatology , University of Basel, University Children's Hospital , Basel , Switzerland.
  2. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France ; Clocheville Hospital , Tours , France.
  3. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France ; Department of Pediatrics , Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris , Paris , France.
  4. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France.
  5. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France ; Department of Microbiology and Immunology, Pediatric Immunology and Pediatric Rheumatology , KU Leuven-University of Leuven, University Hospitals Leuven , Leuven , Belgium.
  6. Department of Paediatric Immunology, Hematology and Rheumatology and Institut IMAGINE , Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris , Paris , France ; Université Paris-Descartes , Paris , France.

PMID: 26509061 PMCID: PMC4613174 DOI: 10.1136/rmdopen-2014-000036

Abstract

OBJECTIVES: To analyse the effect of biological agents (BAs) in terms of achieving inactive disease (ID) or clinical remission (CR) in patients with systemic juvenile idiopathic arthritis (SJIA), to describe effects of switching or discontinuing a BA and to assess the proportion of patients able to maintain ID or CR off steroids and after withdrawing BA therapy.

METHODS: Retrospective study in a French paediatric rheumatology reference centre using the CEMARA (CEntre des MAladies RAres) register.

RESULTS: Seventy-seven patients were included with a cumulative follow-up of 245.5 patient-years (median 1.1, range 0.5-8.0). On a first BA, ID was achieved in 37 patients, including 1 patient out of 12 patients on etanercept, 26 patients out of 51 on anakinra and 7 out of 10 on canakinumab. One patient on abatacept and two patients on tocilizumab also achieved ID. Switching of BA was common. The switch to a second (n=34), third (n=18) or fourth (n=4) BA resulted in ID in a further 13 patients, either on canakinumab (n=6) or tocilizumab (n=7). At last follow-up, 40 patients were in CR (27 patients off steroids, 5 patients having never received steroid treatment), either on (n=29) or off (n=11) BA.

CONCLUSIONS: In this series of patients with SJIA, interleukin-1 inhibitors were associated with a higher proportion of ID than tumour necrosis factor inhibitors when used as first BA. Switching allowed some patients to achieve ID when treated with canakinumab or tocilizumab. CR was eventually achieved in more than half of the patients.

Keywords: DMARDs (biologic); Juvenile Idiopathic Arthritis; Outcomes research; TNF-alpha

References

  1. Arthritis Rheum. 2009 May 15;61(5):658-66 - PubMed
  2. J Rheumatol. 2005 May;32(5):935-42 - PubMed
  3. Arthritis Rheum. 2003 Apr;48(4):1093-101 - PubMed
  4. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1551-63 - PubMed
  5. N Engl J Med. 2012 Dec 20;367 (25):2396-406 - PubMed
  6. Ann Rheum Dis. 2009 Apr;68(4):519-25 - PubMed
  7. Ann Rheum Dis. 2009 Apr;68(4):552-7 - PubMed
  8. Stud Health Technol Inform. 2010;160(Pt 1):481-5 - PubMed
  9. Arthritis Rheum. 2008 May;58(5):1505-15 - PubMed
  10. Arthritis Rheum. 2008 May;58(5):1496-504 - PubMed
  11. Ann Rheum Dis. 2011 May;70(5):747-54 - PubMed
  12. Arthritis Rheum. 2013 Sep;65(9):2486-96 - PubMed
  13. Arthritis Rheum. 2006 May;54(5):1595-601 - PubMed
  14. Ann Rheum Dis. 2015 Jul;74(7):1379-86 - PubMed
  15. J Rheumatol. 2014 Apr;41(4):759-67 - PubMed
  16. Nat Rev Rheumatol. 2011 Jun 07;7(7):416-26 - PubMed
  17. Ann Rheum Dis. 2013 May;72(5):721-7 - PubMed
  18. Arthritis Rheumatol. 2014 Apr;66(4):1034-43 - PubMed
  19. J Clin Rheumatol. 2009 Jun;15(4):161-4 - PubMed
  20. J Rheumatol. 2004 Feb;31(2):390-2 - PubMed
  21. Ann Rheum Dis. 2004 Dec;63(12):1638-44 - PubMed
  22. Best Pract Res Clin Rheumatol. 2002 Jul;16(3):347-60 - PubMed
  23. J Rheumatol. 2000 Feb;27(2):491-6 - PubMed
  24. N Engl J Med. 2012 Dec 20;367 (25):2385-95 - PubMed
  25. J Exp Med. 2005 May 2;201(9):1479-86 - PubMed
  26. Ann Rheum Dis. 2008 Mar;67(3):302-8 - PubMed
  27. Arthritis Rheum. 2011 Feb;63(2):545-55 - PubMed
  28. Arthritis Rheum. 2005 Nov;52(11):3554-62 - PubMed
  29. Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 - PubMed
  30. Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82 - PubMed
  31. Ann Rheum Dis. 2009 May;68(5):635-41 - PubMed

Publication Types